Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

1,001

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

October 31, 2016

Conditions
Acne
Interventions
DRUG

Epiduo® Forte Gel

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

DRUG

Adapalene and Benzoyl Peroxide Gel

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

DRUG

placebo gel

vehicle used as placebo

Trial Locations (20)

27262

Site 106, High Point

32256

Site 119, Jacksonville

33015

Site 114, Miami

33027

Site 116, Miramar

33175

Site 115, Miami

33511

Site 101, Brandon

46032

Site 105, Carmel

47150

Site 120, New Albany

54501

Site 108, Rhinelander

60005

Site 102, Arlington Heights

85202

Site 103, Mesa

85712

Site 109, Tucson

89052

Site 107, Henderson

90813

Site 110, Long Beach

91790

Site 113, West Covina

92108

Site 104, San Diego

92210

Site 111, Los Angeles

92804

Site 112, Anaheim

Unknown

Site 117, Belize City

Site 118, Belize City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT02651220 - Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter